NCT04362150 (LIINC) is a clinical trial in COVID, sponsored by University of California, San Francisco.

Who is sponsoring NCT04362150?

NCT04362150 is sponsored by University of California, San Francisco.

Is NCT04362150 still recruiting?

NCT04362150 is currently recruiting now. Last updated 12 June 2025.

Last reviewed 2025-06-12 · How we verify

NCT04362150: LIINC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long-term Impact of Infection With Novel Coronavirus (COVID-19)

Recruiting now Last updated 12 June 2025

What this trial tests

trial in COVID in 800 participants. Currently enrolling.

Timeline

21 April 2020

Primary endpoint
31 December 2030

31 December 2030

Quick facts

Lead sponsor	University of California, San Francisco
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	800
Start date	21 April 2020
Primary completion	31 December 2030
Estimated completion	31 December 2030
Sites	1 location across United States

Conditions studied

COVID — all drugs for COVID →

Sponsor

University of California, San Francisco

Who can join

Adults 18 to 100, any sex, with COVID. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

LIINC is a study of volunteers who were previously infected with SARS-CoV-2 (also known as novel coronavirus or COVID-19) who have recovered from acute infection. The study is designed to provide a specimen bank of samples with carefully characterized clinical data. LIINC specimens will be used to examine multiple questions involving the virologic, immunologic, and host factors involved in COVID-19, with a focus on understanding variability in the long-term immune response between individuals.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Post-acute COVID-19 syndrome.
Nalbandian A, Sehgal K, Gupta A, Madhavan MV, et al · · 2021 · cited 3355× · PMID 33753937 · DOI 10.1038/s41591-021-01283-z
Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2.
Yin K, Peluso MJ, Luo X, Thomas R, et al · · 2024 · cited 253× · PMID 38212464 · DOI 10.1038/s41590-023-01724-6
Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Peluso MJ, Lu S, Tang AF, Durstenfeld MS, et al · · 2021 · cited 252× · PMID 34677601 · DOI 10.1093/infdis/jiab490
Chronic viral coinfections differentially affect the likelihood of developing long COVID.
Peluso MJ, Deveau TM, Munter SE, Ryder D, et al · · 2023 · cited 173× · PMID 36454631 · DOI 10.1172/jci163669
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay.
Peluso MJ, Takahashi S, Hakim J, Kelly JD, et al · · 2021 · cited 137× · PMID 34330709 · DOI 10.1126/sciadv.abh3409
SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19.
Peluso MJ, Deeks SG, Mustapic M, Kapogiannis D, et al · · 2022 · cited 105× · PMID 35285072 · DOI 10.1002/ana.26350
Cellular and molecular biomarkers of long COVID: a scoping review.
Espín E, Yang C, Shannon CP, Assadian S, et al · · 2023 · cited 87× · PMID 37037165 · DOI 10.1016/j.ebiom.2023.104552
Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection.
Peluso MJ, Sans HM, Forman CA, Nylander AN, et al · · 2022 · cited 76× · PMID 35701186 · DOI 10.1212/nxi.0000000000200003

Verify or expand the search:

Other recruiting trials for COVID

Currently open trials in the same condition.

NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04362150 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 12 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04362150.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing